New Biotechnology Technologies: MIT Enterprise Forum Nov. 15

News Release            For Information:
                     
Connie Luthy    214-827-6556
                             214-673-6556 cell   
                  Mary Swensen 972-423-4125
                                214-695-1765 cell
                  Mary Langford 972-517-7887

MIT Forum to Present Biomedical Technology:
Where Biology, Medicine and High Tech Intersect"

Dallas, Texas - - October 27, 2000.     The MIT Enterprise Forum of Dallas -Fort Worth, Inc. November 15 program will explore new biomedical technologies as part of its Future Technologies" series. In partnership with the Dallas Forum for BioMedical Technology, the breakfast program will be at the UTDallas Conference Center room CN-1.112 from 7:00 to 9:00 am. Reservations can be made by calling (972) 517-7887, emailing mitforum@juno.com or by going to www.mitforum.com. The cost is $30 per person. Students with student identification may attend for $10.

As terms such as Biotechnology, Biomedical Technology, Biopharmaceuticals, and Bioinformatics enter the mainstream of business news, investor and scientific excitement over the merging of high tech, biology and medical disciplines is growing. This new paradigm provides the backdrop for the November MIT Forum, which features three companies poised at the leading edge of this new revolution. Chief executive officers (CEOs) of Texas-based Cytoclonal Pharmaceutics Inc. (CPI); Hybrigen, Inc.; and International Isotopes Incorporated (I3) will present the visions of their companies as they lead the way into the fast-growing biomedical business sector.
   
The moderator will be Connie L. Luthy, Ph.D., MBA, CEO and Chief Strategist of The LUTHY Group - Drug Research & Development Consultants. The panel will include Arthur Bollon, Ph.D, founder, chairman, CEO of CPI; David Edwards, Ph.D. founder, president, CEO of Hybrigen; and David Camp, Ph.D., president, CEO of I3.

We are proud to be partnering with the Dallas Forum for BioMedical Technology to bring three such leading companies before the DFW business community," said Neil Kaden, MIT Forum Chairman. Our moderator, Dr. Connie L. Luthy, works at the national and international levels and has done much to develop a sense of community in the local biomedical industries. I believe they will have an exciting story to tell the entrepreneurs and investors who attend our forums. Since our Future Technologies Series focuses on where leading industries are heading, I expect that this one, like our previous program on nanotechnology, will be talked about for some time."

The Dallas Forum for BioMedical Technology (DFBT) is co-sponsoring the November 15th MIT Forum. The DFBT is a non-profit forum for information exchange on the commercialization of biology, chemistry, medicine, bioengineering and related technology. Membership information is available at the DFBT Website http://community.dallasnews.com/dmn/dfbt.
.

   CPI, http://cytoclonal.com, is a biopharmaceutical company that specializes in developing therapeutic and diagnostic products to treat and prevent cancer and infectious diseases. The company was founded in 1991 and completed an initial public offering (IPO) raising $11.5 million in 1995. The company occupies 22,500 square feet of office and laboratory space. CPIs lead programs include the improved production of paclitaxel (active ingredient in Taxol) using fermentation and genetic engineering. This program alone is potentially worth up to $50 million or more in royalties from Bristol-Myers Squibb.

Hybrigen, www.flash.net/~promethe, was founded in late 1998 after its founder, Dr. Edwards, completed his Ph.D. in Genetics and Development at UTSouthwestern. His eight years of experience using specialized in vivo proteomics test systems and experience as Team Leader of a high-throughput functional genomics screening group were instrumental in developing his vision for the privately held biotechnology company. At Hybrigen invention of cutting-edge platform technologies are accelerating the in-house development and out-licensing of Bioinformatics Templates" required by pharmaceutical, biotechnology and agribusiness customers to accelerate their own high-value product development programs. Hybrigens objective is to become a leader in the explosively growing proteomics sector of business-to-business biotech commerce within the next 3 years. Dr. Edwards is currently completing medical training at UTSW.

I3, http://www.intiso.com, was founded in 1995. I3 is a world leader in commercial, environmentally safe production of high-quality radioisotopes, pharmaceutical grade radioisotopes, and state-of-the-art diagnostic/therapeutic products for medicine. I3 acquired the 70 MeV Linear Accelerator from the now defunct U.S. Superconducting Super Collider (SSC) project and has been commended by the Texas State Legislature for utilization of the SSC assets in the medical field. I3 successfully completed an IPO in 1997.

Future MIT Forums will explore creative financial solutions for high-tech entrepreneurs, and the next Future Technology Series" forum will explore new broadband wireless technologies. The MIT Forum Website, www.mitforum.com, offers advance information on upcoming programs, an opportunity to register for the MIT Forum mailing list, and descriptions of past forums.

The MIT Forums mission is to support the development of technology-oriented companies in their early stages and to nurture the infrastructure to develop these companies in North Texas. The MIT Forum pursues these goals through case study presentations of emerging companies, through issues forums, through satellite broadcasts featuring speakers from MIT, and through other special events.

   The MIT Enterprise Forum of Dallas – Fort Worth, Inc. is a nonprofit organization affiliated with the MIT Enterprise Forum, Inc. at the Massachusetts Institute of Technology in Cambridge, Massachusetts. Operating as the MIT Enterprise Forum at UT-Dallas and as the MIT Forum, it is managed by a volunteer executive committee supported by a paid part-time executive administrator. The MIT Forum is funded by its sponsors, the MIT Alumni Association and: FigDesign, Haynes and Boone, Jackson Walker LLP, KPMG, Munsch Hardt Kopf & Harr, PricewaterhouseCoopers, Roach Howard Smith & Hunter, R.R. Donnelley Financial, Satama Interactive, Southwest Securities, STARTech Business Development Center, and the UTDallas School of Management, and maintains alliance relationships with a number of local entrepreneurial non-profit support groups.

Executive committee members are MIT Forum Chairman and Chief Operating Officer Neil Kaden, Nortel Networks; MIT Enterprise Forum Dallas-Fort Worth founder Patrick Antaki, Willow Technology; Matt Blanton, STARTech; Larry W. Calton, Jr., KPMG; Bill Dedmon, Southwest Securities; Karen Farris, Roach Howard Smith & Hunter; David Fiegenschue, FigDesign; MIT Forum Vice-Chair of Programs Elizabeth Frank, NetCapital, Inc.; Paul Gaddis, UTDallas School of Management; Paul Gaither, Satama Interactive; Custis Hogue, R.R. Donnelley Financial; Barbara Johnson, UTDallas School of Management; G.K. Kalyanarum, UTDallas School of Management and MIT Club of DFW; William S. Kleinman, Haynes and Boone; MIT Forum Vice-Chair of Alliances David Kohl, Roach Howard Smith & Hunter; Mark Kopidlansky, Munsch Hardt Kopf & Harr; MIT Forum Executive Committee Secretary Mary Langford; Bart Reichert, PricewaterhouseCoopers; David Springate, UTDallas School of Management; MIT Forum Vice-Chair of Marketing Mary Swensen, Swensen Communications; and Steven Thrasher, Jackson Walker LLP.

# # #